Indivior fails to overturn decision preventing rival from selling copycat product

Writer, Stock Market Wire
Tuesday, February 5, 2019 - 08:13

Indivior said Tuesday it had failed in its attempt to appeal against a decision that would allow rival Dr. Reddy's Laboratories from selling a generic version of the company's opioid addiction treatment

The U.S. Court of Appeals for the Federal Circuit had denied Indivior's motion for rehearing following the decision to vacate the preliminary injunction granted against Dr. Reddy's Laboratories. The CAFC stated its mandate was currently set to issue on February 11, 2019.

After the mandate issues, Dr. Reddy's Laboratories would no longer be prevented from selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film product in the U.S.

But Indivior said it intended to file an emergency motion with the court to request the preliminary injunction remain in place until the company's appeal against the District of Delaware's decision was heard.

The District of Delaware previously said that Dr. Reddy's Laboratories did not infringe on one of Indivior's patents.

'We are disappointed that the CAFC has denied Indivior's motion for rehearing,' said Shaun Thaxter, CEO of Indivior.

'While we ultimately believe in the strength of our patent portfolio, we acknowledge that the company faces major disruption in the immediate future from a potential material and rapid loss of market share by our SUBOXONE film product to generic buprenorphine/naloxone sublingual film competition.'

At 8:13am: (LON:INDV) Indivior Plc share price was -24.09p at 89.06p

Related content

Indivior upgrades profit outlook on stronger-than-expected performance of opioid addiction drug

Drug company Indivior upgraded its full-year profit outlook following stronger-than-expected net revenue performance as sales of its opioid addiction treatment had fared better than expected...

Tue, 15/10/2019 - 08:02

Indivior profits rises in Q2 as opioid addiction treatment fares better than expected

Drugmaker Indivior reported a rise in profits on stronger-than-expected second-quarter performance, during which its opioid-addiction treatment loss less market share than expected following the launch...

Wed, 31/07/2019 - 09:53

Reckitt and Indivior soar on US settlement and shares in housebuilders lifted by property market data

“UK and Asian stocks followed the upwards trend seen last night in the US after the Fed signalled an interest rate cut. The FTSE 100...

Thu, 11/07/2019 - 11:20

Indivior raises guidance as opioid addiction treatment fares better than expected in H1

Drugmaker Indivior raised its earnings guidance on a stronger-than-expected first half, during which its opioid-addiction treatment loss less market share than expected following the launch...

Thu, 11/07/2019 - 08:26

Reckitt Benckiser’s new chief executive has a difficult job ahead


The retirement of company veteran Rakesh Kapoor as chief executive potentially spared the board of consumer goods firm Reckitt Benckiser (RB.) from a...

Thu, 20/06/2019 - 00:00